MediWound (NASDAQ:MDWD) Stock Passes Below 200-Day Moving Average - Time to Sell?

Key Points

• MediWound shares fell below their 200‑day moving average, trading as low as $16.73 and last at $16.96 versus a 200‑day MA of $17.86, signaling technical weakness.
• Analyst views are mixed — MarketBeat shows a consensus rating of Hold with a $31.67 target, while individual ratings range from "strong sell" to "buy" (HC Wainwright's target $36).
• Fundamentals: Q4 EPS of ($0.56) beat estimates but revenue missed ($1.87M vs. $2.09M); the company remains unprofitable with negative net margin and ROE and a market cap around $217M.

MediWound Ltd. (NASDAQ:MDWD - Get Free Report) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $17.86 and traded as low as $16.73. MediWound shares last traded at $16.96, with a volume of 82,317 shares traded.

Wall Street Analyst Weigh In

A number of research firms recently commented on MDWD. Weiss Ratings reissued a "sell (d-)" rating on shares of MediWound in a research note on Thursday, January 22nd. Wall Street Zen lowered MediWound from a "hold" rating to a "strong sell" rating in a research note on Saturday, March 7th. Finally, HC Wainwright reiterated a "buy" rating and issued a $36.00 price objective (up from $31.00) on shares of MediWound in a report on Friday, November 21st. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $31.67.

MediWound Price Performance

The stock has a market cap of $217.26 million, a PE ratio of -8.08 and a beta of 0.13. The company has a 50 day moving average price of $17.38 and a two-hundred day moving average price of $17.86.

MediWound (NASDAQ:MDWD - Get Free Report) last issued its earnings results on Thursday, March 5th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.09. The company had revenue of $1.87 million for the quarter, compared to analysts' expectations of $2.09 million. MediWound had a negative net margin of 140.80% and a negative return on equity of 65.79%. As a group, equities analysts predict that MediWound Ltd. will post -2.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of MDWD. Rhumbline Advisers raised its position in MediWound by 4.4% in the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company's stock worth $176,000 after acquiring an additional 481 shares during the period. Russell Investments Group Ltd. grew its position in shares of MediWound by 69.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 649 shares during the period. BNP Paribas Financial Markets increased its stake in shares of MediWound by 90.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 723 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company's stock worth $85,000 after purchasing an additional 999 shares in the last quarter. Finally, Quarry LP bought a new position in MediWound in the 4th quarter worth $26,000. 46.83% of the stock is owned by hedge funds and other institutional investors.

About MediWound

MediWound Ltd. NASDAQ: MDWD is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company's lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.